ERBB2 and neoplasm: Thus, we attempted to evaluate the prognostic role of PgR using a cut-off point of 20% and determine whether this threshold is appropriate to differentiate PgR-positive from PgR-negative disease and correctly elucidate the clinicopathologic features of ER+/PgR+/HER2- and ER+/PgR-/HER2- tumours.